Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
A Prospective Randomized Phase II Trial of Long-Course Chemoradiotherapy or Short-Course Radiotherapy Combined With CAPOX, PD-1 Antibody, and a COX-2 Inhibitor for Microsatellite Stable Locally Advanced Rectal Cancer (SERRAC)
Fudan University
138 participants
Aug 28, 2025
INTERVENTIONAL
Conditions
Summary
SERRAC is a prospective, multicentre, randomized phase II trial. 138 LARC (T3-4/N+M0, distance from anal verge ≤10cm) patients will be treated with neoadjuvant therapy and assigned to Group A and Group B (1:1). Group 1 receives LCRT (50Gy/25Fx) followed by 3 cycles of CAPOX.Group 2 receives SCRT (25Gy/5Fx) followed by 4 cycles of capecitabine plus oxaliplatin (CAPOX) chemotherapy and PD-1 antibody. The COX2 inhibitor celecoxib 200 mg was started orally twice a day during chemotherapy until the end of neoadjuvant treatment.TME surgery is scheduled after TNT while a watch and wait (W\&W) option can be applied to patients achieving clinical complete response (cCR). The primary endpoint is complete response (CR, pathological complete response \[pCR\] plus cCR) rate. The secondary endpoints include the grade 3-4 acute adverse effects (AE) rate, anal preservation rate, 3-year DFS rate, etc.
Eligibility
Inclusion Criteria11
- Age 18-75 years, gender not limited
- Pathologically confirmed rectal adenocarcinoma
- ≤10 cm from the anus
- Baseline stage T3-4/N+
- No distant metastasis
- MSI/MMR status MSS/pMMR
- Karnofsky performance status score ≥70
- No prior chemotherapy or other anti-cancer treatment prior to enrollment
- No prior immunotherapy prior to enrollment
- Ability to comply with the study protocol
- Written informed consent
Exclusion Criteria10
- Pregnancy or breast-feeding women;
- Known history of other malignancies within 5 years;
- Known history of previous anti-tumor treatment, including radiotherapy, chemotherapy, immune checkpoint inhibitors, T cell-related therapy, etc;
- Known history of severe neurological or mental illness (such as schizophrenia, dementia or epilepsy);
- Current severe cardiac disease (cardiac dysfunction and arrhythmia), renal dysfunction and liver dysfunction;
- Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment;
- Uncontrolled infection which needs systemic therapy;
- Active autoimmune disease or immunodeficiencies, known history of organ transplantation or systematic use of immunosuppressive agents;
- Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1 to 2 antibody positive), active syphilis infection, active pulmonary tuberculosis infection
- Allergic to any component of the therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Long-course radiation: 50Gy/25Fx
Oxaliplatin: 130mg/m2 d1 q3w
Xeloda
celecoxib 200 mg orally twice a day
Short-course radiotherapy: 25Gy/5Fx
Serplulimab 300mg, d1, q3w
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07150949